The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome

Crest detail over the main portal; A school of drawing and painting has existed in Toulouse since 1680. Dominique Ingres was among students of the school, 1791 to 1796. In 1804 , the school, now Royal Academy of Fine Arts, settled in a part of the former Augustinian convent (now the Musée des Augustins). This was the first provincial art school and the only one designated "royal" outside of Paris. In 1892 the school moved to its present location near La Daurade. The monumental facade, decorated with allegorical statues of Painting, Sculpture, Printmaking and Architecture was added in 1895. Source: Wikipedia; http://en.wikipedia.org/wiki/Main_Page (accessed 5/18/2011

2009

ABSTRACT of a statistical model that gives a good, low-dimensional representation of the time courses and a mathematical model that estimates biologically interesting parameters. The parameters of these models were then compared between treatments strategies. This approach is useful for understanding the effects of different tyrosine kinase inhibitors on individual cell populations and can also be applied to other cancer types treated with targeted agents

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

We investigated the impact of carrying more than one BCR-ABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8%) of 92 patients carrying mutations had more than one mutation: 4 (4%) in chronic phase, 2 (2%) in accelerated phase, and one (1 %) in blast phase. The cytogenetic response rate to second generation TKIs for patients with no, one, or more than one mutation was 88%, 69%, 50% (P=0.03) in chronic phase, 54%, 42%, 50% in accelerated phase (P=0.67), and 35%, 25%, 0% (P=0.63) in blast phase, respectively. No differences were observed in event free survival or overall survival in accelerated or blast phase according to their mutational status. However, the 4-year event free survival rates among patients in chronic phase with no, one, or more than one BCR-ABL1 mutation were 56%, 49%, and 0%, respectively (P=0.02), with overall survival rates of 91%, 69%, and 75%, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation